This site is intended only for Australian Healthcare Professionals
Discontinue XELJANZ 10 mg BID after 16 weeks if an adequate response is not achieved. Beyond induction, use of 10 mg BID should be limited to appropriate patientse and used for the shortest duration possible. The lowest effective dose needed to maintain response should be used.3
BID=twice daily; JAK: Janus kinase; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis; VTE=venous thromboembolism.
Learn more about the XELJANZ safety profile
Learn about dosing with XELJANZ, the first JAKi approved for UC
Find out more about the JAKi with the longest market experience in RA, PsA, and UC
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
XELJANZ should only be used if no suitable treatment alternatives are available in patients:
See PI for details, Section 4.4 Special Warnings and Precautions for Use: Mortality; Major Adverse Cardiovascular Events (including Myocardial Infarction); Thrombosis; Malignancy and Lymphoproliferative Disorder (excluding Nonmelanoma Skin Cancer [NMSC]); Skin Cancer and Use in the Elderly.
Before prescribing, please review full Product Information available here.
PBS Information: Authority required for the treatment of adults with severe active rheumatoid arthritis and for adults with severe psoriatic arthritis and for adults with moderate-to-severe ulcerative colitis. Refer to the PBS Schedule for full authority information. This product is not listed on the PBS for juvenile idiopathic arthritis, juvenile psoriatic arthritis, or ankylosing spondylitis.
To access further materials, resources and receive communication about Pfizer medicines and vaccines.
The site is intended for Australian healthcare professionals.
©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.